I think it’s being a tad overoptimistic to think we might catch up to Stoke’s ~A$1.2bn market cap by the end of this year.
Stoke has a 2.5 – 3 year lead on PYC in getting its lead program into clinic trials. It already has some positive interim readouts from that program. Cash on hand at CY end was almost A$300m. In addition, since then, Stoke has partnered a couple of other programs with Acadia and received A$80m to advance those programs.
PYC, page-50
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
-0.005(4.35%) |
Mkt cap ! $513.2M | |||
| Open | High | Low | Value | Volume |
| 11.5¢ | 11.8¢ | 11.0¢ | $297.5K | 2.621M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 1372418 | 11.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.5¢ | 390472 | 6 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| PYC (ASX) Chart |